Molecular Medicine

, Volume 21, Issue 1, pp 739–748 | Cite as

Signatures of miR-181a on the Renal Transcriptome and Blood Pressure

  • Francine Z. Marques
  • Simon P. R. Romaine
  • Matthew Denniff
  • James Eales
  • John Dormer
  • Ingrid M. Garrelds
  • Lukasz Wojnar
  • Katarzyna Musialik
  • Barbara Duda-Raszewska
  • Bartlomiej Kiszka
  • Magdalena Duda
  • Brian J. Morris
  • Nilesh J. Samani
  • A. H. Jan Danser
  • Pawel Bogdanski
  • Ewa Zukowska-Szczechowska
  • Fadi J. Charchar
  • Maciej Tomaszewski
Research Article


MicroRNA-181a binds to the 3′ untranslated region of messenger RNA (mRNA) for renin, a rate-limiting enzyme of the renin-angiotensin system. Our objective was to determine whether this molecular interaction translates into a clinically meaningful effect on blood pressure and whether circulating miR-181a is a measurable proxy of blood pressure. In 200 human kidneys from the TRANScriptome of renaL humAn TissuE (TRANSLATE) study, renal miR-181a was the sole negative predictor of renin mRNA and a strong correlate of circulating miR-181a. Elevated miR-181a levels correlated positively with systolic and diastolic blood pressure in TRANSLATE, and this association was independent of circulating renin. The association between serum miR-181a and systolic blood pressure was replicated in 199 subjects from the Genetic Regulation of Arterial Pressure of Humans In the Community (GRAPHIC) study. Renal immunohistochemistry and in situ hybridization showed that colocalization of miR-181a and renin was most prominent in collecting ducts where renin is not released into the systemic circulation. Analysis of 69 human kidneys characterized by RNA sequencing revealed that miR-181a was associated with downregulation of four mitochondrial pathways and upregulation of 41 signaling cascades of adaptive immunity and inflammation. We conclude that renal miR-181a has pleiotropic effects on pathways relevant to blood pressure regulation and that circulating levels of miR-181a are both a measurable proxy of renal miR-181a expression and a novel biochemical correlate of blood pressure.



We thank Boye Schnack Nielsen from Bioneer S/A (Denmark) for his help with the in situ hybridization and immunohistochemistry. This work was supported by grants from British Heart Foundation (PG/12/9/29376 to M Tomaszewski and J Eales), the National Health & Medical Research Council of Australia (NHMRC project grant 526662 to FJ Charchar) and the Federation University Australia Self-Sustaining Regions Research and Innovation Initiative, an Australian Government Collaborative Research Network grant (to FJ Charchar and FZ Marques). FZ Marques is supported by a NHMRC (APP1052659) and National Heart Foundation (PF12M6785) co-shared Early Career Fellowships. SPR Romaine is supported by Health Education East Midlands.

Supplementary material

10020_2015_2101739_MOESM1_ESM.pdf (940 kb)
Supplementary material, approximately 939 KB.


  1. 1.
    Rapsomaniki E, et al. (2014) Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 383:1899–911.CrossRefGoogle Scholar
  2. 2.
    Charchar F, Zimmerli L, Tomaszewski M. (2008) The pressure of finding human hypertension genes: new tools, old dilemmas. J. Hum. Hypertens. 22:821–8.CrossRefGoogle Scholar
  3. 3.
    Iaconetti C, Gareri C, Polimeni A, Indolfi C. (2013) Non-coding RNAs: the “dark matter” of cardiovascular pathophysiology. Int. J. Mol. Sci. 14:19987–20018.CrossRefGoogle Scholar
  4. 4.
    Marques FZ, Booth SA, Charchar FJ. (2015) The emerging role of non-coding RNA in essential hypertension and blood pressure regulation. J. Hum. Hypertens. 29:459–67.CrossRefGoogle Scholar
  5. 5.
    Romaine SP, Tomaszewski M, Condorelli G, Samani NJ. (2015) MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart. 101:921–8.CrossRefGoogle Scholar
  6. 6.
    Hamid SM, Akgul B. (2014) Master regulators of posttranscriptional gene expression are subject to regulation. Methods Mol Biol. 1107:303–10.CrossRefGoogle Scholar
  7. 7.
    Pasquinelli AE. (2012) MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat. Rev. Genet. 13:271–82.CrossRefGoogle Scholar
  8. 8.
    Creemers EE, Tijsen AJ, Pinto YM. (2012) Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ. Res. 110:483–95.CrossRefGoogle Scholar
  9. 9.
    Marques FZ, et al. (2011) Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs. Hypertension. 58:1093–8.CrossRefGoogle Scholar
  10. 10.
    Jackson KL, et al. (2013) A novel interaction between sympathetic overactivity and aberrant regulation of renin by miR-181a in BPH/2J genetically hypertensive mice. Hypertension. 62:775–81.CrossRefGoogle Scholar
  11. 11.
    Tomaszewski M, et al. (2011) Pathway analysis shows association between FGFBP1 and hypertension. J. Am. Soc. Nephrol. 22:947–55.CrossRefGoogle Scholar
  12. 12.
    Tomaszewski M, et al. (2007) Fibroblast growth factor 1 gene and hypertension: from the quantitative trait locus to positional analysis. Circulation. 116:1915–24.CrossRefGoogle Scholar
  13. 13.
    Tomaszewski M, et al. (2015) Renal mechanisms of association between fibroblast growth factor 1 and blood pressure. J. Am. Soc. Nephrol. 26:3151–60.CrossRefGoogle Scholar
  14. 14.
    Tomaszewski M, et al. (2010) Genetic architecture of ambulatory blood pressure in the general population: insights from cardiovascular gene-centric array. Hypertension. 56:1069–76.CrossRefGoogle Scholar
  15. 15.
    Ehret GB, Caulfield MJ. (2013) Genes for blood pressure: an opportunity to understand hypertension. Eur. Heart J. 34:951–61.CrossRefGoogle Scholar
  16. 16.
    Smyth GK. (c2005) limma: Linear Models for Microarray Data. In: Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S (eds.) Springer, New York, pp. 397–420.CrossRefGoogle Scholar
  17. 17.
    Subramanian A, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102:15545–50.CrossRefGoogle Scholar
  18. 18.
    GTEx Consortium. (2013) The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45:580–5.CrossRefGoogle Scholar
  19. 19.
    Abd-Allah NM, Hassan FH, Esmat AY, Hammad SA. (2004) Age dependence of the levels of plasma norepinephrine, aldosterone, renin activity and urinary vanillylmandelic acid in normal and essential hypertensives. Biol. Res. 37:95–106.CrossRefGoogle Scholar
  20. 20.
    Uckaya G, et al. (1999) Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. Horm. Metab. Res. 31:435–8.CrossRefGoogle Scholar
  21. 21.
    Vetter H, Glanzer K, Vetter W. (1980) Essential hypertension: relationship between renin and blood pressure. Clin. Exp. Hypertens. 2:553–61.CrossRefGoogle Scholar
  22. 22.
    Danser AH, Derkx FH, Schalekamp MA, Hense HW, Riegger GA, Schunkert H. (1998) Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J. Hypertens. 16:853–62.CrossRefGoogle Scholar
  23. 23.
    He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. (1999) The renin-angiotensin system and blood pressure: differences between blacks and whites. Am. J. Hypertens. 12:555–62.CrossRefGoogle Scholar
  24. 24.
    Lucas CP, et al. (1974) Disturbed relationship of plasma-renin to blood-pressure in hypertension. Lancet. 2:1337–9.CrossRefGoogle Scholar
  25. 25.
    Williams B, Baschiera F, Lacy PS, Botha J, Prescott MF, Brunel P. (2013) Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise. J. Renin Angiotensin Aldosterone Syst. 14:56–66.CrossRefGoogle Scholar
  26. 26.
    He FJ, Markandu ND, MacGregor GA. (2001) Importance of the renin system for determining blood pressure fall with acute salt restriction in hypertensive and normotensive whites. Hypertension. 38:321–5.CrossRefGoogle Scholar
  27. 27.
    Medrano S, Monteagudo MC, Sequeira-Lopez ML, Pentz ES, Gomez RA. (2012) Two microRNAs, miR-330 and miR-125b-5p, mark the juxtaglomerular cell and balance its smooth muscle phenotype. Am. J. Physiol. Renal Physiol. 302:F29–37.CrossRefGoogle Scholar
  28. 28.
    Hu Y, Li P, Hao S, Liu L, Zhao J, Hou Y. (2009) Differential expression of microRNAs in the placentae of Chinese patients with severe pre-eclampsia. Clin. Chem. Lab Med. 47:923–9.PubMedGoogle Scholar
  29. 29.
    Mayor-Lynn K, Toloubeydokhti T, Cruz AC, Chegini N. (2011) Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor. Reprod. Sci. 18:46–56.CrossRefGoogle Scholar
  30. 30.
    Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA. (2011) Intratubular renin-angiotensin system in hypertension. Hypertension. 57:355–62.CrossRefGoogle Scholar
  31. 31.
    Prieto-Carrasquero MC, Botros FT, Kobori H, Navar LG. (2009) Collecting duct renin: A major player in angiotensin II-dependent hypertension. J. Am. Soc. Hypertens. 3:96–104.CrossRefGoogle Scholar
  32. 32.
    Ramkumar N, Stuart D, Rees S, Hoek AV, Sigmund CD, Kohan DE. (2014) Collecting duct-specific knockout of renin attenuates angiotensin II-induced hypertension. Am. J. Physiol. Renal Physiol. 307:F931–8.CrossRefGoogle Scholar
  33. 33.
    Ramkumar N, Ying J, Stuart D, Kohan DE. (2013) Overexpression of renin in the collecting duct causes elevated blood pressure. Am J. Hypertens. 26:965–72.CrossRefGoogle Scholar
  34. 34.
    Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. (2008) The impact of microRNAs on protein output. Nature. 455:64–71.CrossRefGoogle Scholar
  35. 35.
    Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. (2008) Wide-spread changes in protein synthesis induced by microRNAs. Nature. 455:58–63.CrossRefGoogle Scholar
  36. 36.
    Li QJ, et al. (2007) miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 129:147–61.CrossRefGoogle Scholar
  37. 37.
    Liu L, et al. (2012) MicroRNA-181a regulates local immune balance by inhibiting proliferation and immunosuppressive properties of mesenchymal stem cells. Stem Cells. 30:1756–70.CrossRefGoogle Scholar
  38. 38.
    Kroesen BJ, et al. (2015) Immuno-miRs: critical regulators of T-cell development, function and ageing. Immunology. 144:1–10.CrossRefGoogle Scholar
  39. 39.
    Xie W, et al. (2013) miR-181a regulates inflammation responses in monocytes and macrophages. PLoS One. 8:e58639.CrossRefGoogle Scholar
  40. 40.
    Xie W, Li Z, Li M, Xu N, Zhang Y. (2013) miR-181a and inflammation: miRNA homeostasis response to inflammatory stimuli in vivo. Biochem. Biophys. Res. Commun. 430:647–52.CrossRefGoogle Scholar
  41. 41.
    Rippo MR, Olivieri F, Monsurro V, Prattichizzo F, Albertini MC, Procopio AD. (2014) MitomiRs in human inflamm-aging: A hypothesis involving miR-181a, miR-34a and miR-146a. Exp. Gerontol. 56C:154–63.CrossRefGoogle Scholar
  42. 42.
    Ouyang YB, Lu Y, Yue S, Giffard RG. (2012) miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. Mitochondrion. 12:213–9.CrossRefGoogle Scholar
  43. 43.
    Harrison DG, Vinh A, Lob H, Madhur MS. (2010) Role of the adaptive immune system in hypertension. Curr. Opin. Pharmacol. 10:203–7.CrossRefGoogle Scholar
  44. 44.
    Lob HE, et al. (2010) Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension. 55:277–83.CrossRefGoogle Scholar
  45. 45.
    Schiffrin EL. (2010) T lymphocytes: a role in hypertension? Curr. Opin. Nephrol. Hypertens. 19:181–6.CrossRefGoogle Scholar
  46. 46.
    Chan SH, Wu KL, Chang AY, Tai MH, Chan JY. (2009) Oxidative impairment of mitochondrial electron transport chain complexes in rostral ventrolateral medulla contributes to neurogenic hypertension. Hypertension. 53:217–27.CrossRefGoogle Scholar
  47. 47.
    de Cavanagh EM, Toblli JE, Ferder L, Piotrkowski B, Stella I, Inserra F. (2006) Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290:R1616–25.CrossRefGoogle Scholar
  48. 48.
    Eirin A, Lerman A, Lerman LO. (2014) Mitochondrial injury and dysfunction in hypertension-induced cardiac damage. Eur. Heart J. 35:3258–66.CrossRefGoogle Scholar
  49. 49.
    Jin K, Vaziri ND. (2014) Salt-sensitive hypertension in mitochondrial superoxide dismutase deficiency is associated with intra-renal oxidative stress and inflammation. Clin. Exp. Nephrol. 18:445–52.CrossRefGoogle Scholar
  50. 50.
    Harrison DG, et al. (2011) Inflammation, immunity, and hypertension. Hypertension. 57:132–40.CrossRefGoogle Scholar
  51. 51.
    Schiffrin EL. (2014) Immune mechanisms in hypertension and vascular injury. Clin. Sci. (Lond). 126:267–74.CrossRefGoogle Scholar
  52. 52.
    Rodriguez-Iturbe B, Pons H, Quiroz Y, Lanaspa MA, Johnson RJ. (2014) Autoimmunity in the pathogenesis of hypertension. Nat. Rev. Nephrol. 10:56–62.CrossRefGoogle Scholar
  53. 53.
    Stewart T, Jung FF, Manning J, Vehaskari VM. (2005) Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension. Kidney Int. 68:2180–8.CrossRefGoogle Scholar
  54. 54.
    Schena FP, Serino G, Sallustio F. (2014) MicroRNAs in kidney diseases: new promising biomarkers for diagnosis and monitoring. Nephrol. Dial. Transplant. 29:755–63.CrossRefGoogle Scholar
  55. 55.
    Kaudewitz D, et al. (2013) Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb. Haemost. 110:609–15.CrossRefGoogle Scholar
  56. 56.
    Willeit P, et al. (2013) Circulating microRNAs as novel biomarkers for platelet activation. Circ. Res. 112:595–600.CrossRefGoogle Scholar
  57. 57.
    Rodwell GEJ, et al. (2004) A transcriptional profile of aging in the kidney. PLoS Biol. 2:e427.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  • Francine Z. Marques
    • 1
  • Simon P. R. Romaine
    • 2
  • Matthew Denniff
    • 2
  • James Eales
    • 2
  • John Dormer
    • 3
  • Ingrid M. Garrelds
    • 4
  • Lukasz Wojnar
    • 5
  • Katarzyna Musialik
    • 6
  • Barbara Duda-Raszewska
    • 7
  • Bartlomiej Kiszka
    • 7
  • Magdalena Duda
    • 7
  • Brian J. Morris
    • 8
  • Nilesh J. Samani
    • 2
    • 9
  • A. H. Jan Danser
    • 4
  • Pawel Bogdanski
    • 6
  • Ewa Zukowska-Szczechowska
    • 7
  • Fadi J. Charchar
    • 1
  • Maciej Tomaszewski
    • 2
    • 10
  1. 1.Faculty of Science and Technology, School of Applied and Biomedical SciencesFederation University AustraliaBallaratAustralia
  2. 2.Department of Cardiovascular SciencesUniversity of LeicesterLeicesterUK
  3. 3.University Hospitals of Leicester NHS TrustLeicesterUK
  4. 4.Division of Pharmacology and Vascular Medicine, Department of Internal MedicineErasmus Medical CentreRotterdamThe Netherlands
  5. 5.Department of Urology and Oncological UrologyPoznan University of Medical SciencesPoznanPoland
  6. 6.Department of Education and Obesity Treatment and Metabolic DisordersPoznan University of Medical SciencesPoznanPoland
  7. 7.Department of Internal MedicineDiabetology and Nephrology, Medical University of SilesiaZabrzePoland
  8. 8.School of Medical SciencesUniversity of SydneySydneyAustralia
  9. 9.Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular DiseaseGlenfield HospitalLeicesterUK
  10. 10.Institute of Cardiovascular SciencesUniversity of ManchesterManchesterUK

Personalised recommendations